NICM
TGTX icon

Neo Ivy Capital Management’s TG Therapeutics TGTX Stock Holding History

Neo Ivy Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-60,833
Closed -$2.02M – 493
2026
Q1 		$2.02M Buy
+60,833
New +$1.81M 0.53% 75
2025
Q2 		– Sell
-6,790
Closed -$268K – 472
2025
Q1 		$268K Buy
+6,790
New +$228K 0.09% 216
2024
Q4 		– Sell
-100,780
Closed -$2.36M – 400
2024
Q3 		$2.36M Buy
+100,780
New +$2.2M 0.76% 44
2023
Q3 		– Sell
-15,099
Closed -$375K – 452
2023
Q2 		$375K Buy
+15,099
New +$390K 0.2% 147
2021
Q4 		– Sell
-5,209
Closed -$101K – 625
2021
Q3 		$101K Sell
5,209
-2,495
-32% -$77.2K 0.12% 245
2021
Q2 		$299K Buy
7,704
+5,635
+272% +$221K 0.3% 127
2021
Q1 		$100K Sell
2,069
-418
-17% -$20.1K 0.11% 244
2020
Q4 		$129K Sell
2,487
-2,721
-52% -$91.9K 0.14% 220
2020
Q3 		$139K Sell
5,208
-1
-0% -$23 0.14% 240
2020
Q2 		$101K Buy
+5,209
New +$83.9K 0.12% 245

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Neo Ivy Capital Management's TGTX Position: Q2 2026 in Review

Neo Ivy Capital Management sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 60,833 shares — an estimated $2.02M sold.

Neo Ivy Capital Management first reported a position in TGTX in Q2 2020 and held it in 10 quarters. The position peaked at $2.36M in Q3 2024. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Neo Ivy Capital Management reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 60,833 TG Therapeutics shares in Q2 2026, an estimated $2.02M.
  • Neo Ivy Capital Management first reported a position in TG Therapeutics in Q2 2020 and held it in 10 quarters.
  • Neo Ivy Capital Management's TG Therapeutics position peaked at $2.36M in Q3 2024.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.